• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Increased inhaled glucocorticoids do not prevent asthma exacerbations in children: The STICS trial

byJames RoebkerandDayton McMillan
March 12, 2018
in Chronic Disease, Emergency, Pediatrics, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In children age 5 to 11 with mild-to-moderate persistent asthma treated with daily inhaled glucocorticoids, quintupling the dose of inhaled glucocorticoids during the initial signs of worsening asthma control did not reduce the rate of severe exacerbations.

2. There was a small but significant decrease in linear growth in children 5 to 7 treated with high-dose inhaled glucocorticoids compared to those in the low-dose group.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: The “yellow zone” of asthma control is used to describe an acute loss of symptom control, during which physicians often increase inhaled glucocorticoid dosage to prevent a costly and potentially dangerous acute exacerbation. However, this common practice has little supporting evidence. The Step Up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS) trial aimed to assess the efficacy and safety of a quintupled dose of inhaled glucocorticoids in children with mild-to-moderate persistent asthma experiencing acute loss of asthma control. The results demonstrated no significant difference in the primary outcome – the rate of severe asthma exacerbations treated with systemic glucocorticoids – between the high-dose and low-dose inhaled glucocorticoid groups. There was also no significant difference in the key secondary outcomes of time to first asthma exacerbation, treatment failure, and unscheduled emergency department visits or hospitalizations for asthma. Unexpectedly, children age 5 to 7 in the high-dose group experienced a significant decrease in growth rate compared to those in the low-dose group.

This was a randomized, double-blinded, parallel group trial that studied a cohort of children with previously little data regarding increasing steroid doses for asthma exacerbation prevention. The study’s single population limits generalizability of results, however, as neither children with asthma who do not take inhaled glucocorticoids regularly nor adults were included. These results suggest large doses of inhaled steroids aren’t associated with a benefit in pediatric asthma control and may stunt growth in certain age groups.

Click to read the study, published in NEJM

Relevant Reading: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children

RELATED REPORTS

Wellness Check: Sleep

Emergency department crowding negative influences outcomes for adults presenting with asthma

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

In-Depth [randomized controlled trial]: This double-blind, parallel group trial studied 254 children age 5 to 11 with mild-to-moderate persistent asthma treated with daily low-dose inhaled glucocorticoids. Participants were randomized in a 1:1 ratio to either low-dose (44 mg, n = 127) or high-dose (220 mg, n = 127) fluticasone for 7 days at the early signs of loss of asthma control. The primary outcome was the rate of severe asthma exacerbations treated with systemic glucocorticoids. Notable secondary outcomes included the time to first asthma exacerbation, treatment failure, unscheduled emergency department or hospitalizations for asthma, and linear growth.

One severe asthma exacerbation treated with systemic glucocorticoids occurred in 38 children in the high-dose group (rate, 0.48 per year; 95% confidence interval [CI], 0.33 to 0.70) versus 30 in the low-dose group (rate, 0.37; 95% CI, 0.25 to 0.55) (relative rate [RR], 1.3; 95% CI, 0.8 to 2.1; p = 0.30). There was no significant differences between groups time to the first severe asthma exacerbation (p = 0.20), emergency department visits (RR, 1.3; 95% CI, 0.8 to 2.4; p = 0.30), or rate of treatment failure (RR, 1.3; p = 0.70). Four hospitalizations occurred in the high-dose group versus zero in the low-dose group; however, the between-group difference was not significant (p = 0.12). The growth rate among children in the high-dose group was 0.23 cm/year less than those in the low-dose group (p = 0.06), and growth rate was significantly lower in children between 5 and 8 high-dose treated patients (0.12 cm/year lower growth per yellow-zone episode, p = 0.02 for comparison with low-dose group). There were no significant differences in patient-reported adverse events between the groups.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthmacorticosteroids
Previous Post

Opioids show no benefit for treating chronic musculoskeletal pain versus non-opioid treatments

Next Post

iPad app that allows patients to order tests doubles colon cancer screening rates in study

RelatedReports

Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

January 19, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Emergency

Emergency department crowding negative influences outcomes for adults presenting with asthma

December 27, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

December 14, 2022
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Chronic Disease

  Vitamin C supplementation in pregnancy improves respiratory function in children of smoking mothers at 5 years of age

December 7, 2022
Next Post
Development of a risk index for colorectal cancer screening

iPad app that allows patients to order tests doubles colon cancer screening rates in study

AAP supports mindfulness of children’s media consumption

Stricter state firearm laws associated with lower rates of firearm suicide and homicide

Late gestation antidepressant use linked to postpartum hemorrhage

No difference between tenofovir and placebo in reducing perinatal transmission of hepatitis B

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options